A New Depression Drug Related To Ketamine Has Been Recommended By An FDA Panel
The influential panel voted 14-2 in favor of Johnson & Johnson's drug esketamine, a treatment developed to treat major depression in patients who have not benefited from at least two different therapies. The panel said the benefits of the nasal spray outweighed the risks.
February 12, 2019 at 07:15PM
via Digg https://nbcnews.to/2THIDEY
No comments:
Post a Comment